© Neurimmune AG (Schlieren, Switzerland)

Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.

Histopathological image of a cross-section from the calf muscle  of a patient who died of Duchenne muscular dystrophy . The image illustrates the extent to which the (red coloured) muscle fibres have been replaced by fat cells (optically empty = white). © CDC

Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.

Syntax prototype © DNA Script

Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.

© Pixabay.com

Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.

Structure of the viral spike protein with omicron mutations shown in red colour. © Markus Hoffmann, Deutsches Primatenzentrum, Göttingen

The new year begins with good news.

© 21st.BIO A/S

Novo Holdings is set to invest €86m in 21st.BIO A/S – a new Danish bioindustrial scale-up company – to boost the production of proteins.

© Novartis AG

Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.

pixaby.com/kschneider2991

Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.

© Depixus

French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.  

© Almirall SA

Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.